摘要
Cytotoxic CD8(+) T cells are the main focus of efforts to understand anti-tumor immunity and immunotherapy. The adoptive transfer of tumor-reactive cytotoxic CD8(+) T lymphocytes expanded and differentiated in vitro has long been considered the primary strategy in adaptive anti-tumor immunity, however, the majority of the transferred tumor antigen-specific CD8(+) T cells differentiated into CD39(+)CD69(+) exhausted progenies, limiting its effects in repressing tumor growth. Contrarily, less attention has been addressed to the role of CD4(+) T cells during tumorigenesis. Using a mouse model of metastatic melanoma, we found that transferring tumor-specific CD4(+) T cells into recipients induces substantial regression of the established metastatic tumors. Notably, in vitro activated CD4(+) T cells developed into cytotoxic CD4(-) T cells in vivo and get exhausted gradually. The blockade of PD-L1 signaling resulted in an expansion of tumor specific CD4(+) T cells, which could better control the established metastatic melanoma. Moreover, the tumor-specific memory CD4(+) T cell can prevent mice from tumor metastasis, and the tumor-specific effector CD4(+) T cells can also mitigate the established metastatic tumor. Overall, our findings suggest a novel mechanism of CD4(+) T cells in curtailing tumor metastasis and confirm their therapeutic role in combination with PD-L1 blockade in cancer immunotherapy. Hence, a better understanding of cytotoxic CD4(-) T cell-mediated tumor regression could provide an alternative choice for patients exhibiting suboptimal or no response to CD8(+) T cell-based immunotherapies.
学科与关键词
- The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesHuang, Qizhao; Wu, Xia; Wang, Zhiming; Chen, Xiangyu; Wang, Lisha; Lu, Yijun; Xiong, Dan; Liu, Qiao; Tian, Yuhan; Lin, Huayu; Guo, Junyi; Wen, Shuqiong; Dong, Wei; Yang, Xiaofan; Yuan, Yuchen; Yue, Zhengliang; Lei, Shun; Wu, Qing; Ran, Ling; Xie, Luoyingzi; Wang, Yifei; Gao, Leiqiong; Tian, Qin; Zhou, Xinyuan; Sun, Beicheng*; Xu, Lifan*; Tang, Zhonghui*; Ye, Lilin*Cell, 2022, 185(22): 4049-+.被引 61
- CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapyXiao, Minglu; Xie, Luoyingzi; Cao, Guoshuai; Lei, Shun; Wang, Pengcheng; Wei, Zhengping; Luo, Yuan; Fang, Jingyi; Yang, Xingxing; Huang, Qizhao; Xu, Lifan; Guo, Junyi; Wen, Shuqiong; Wang, Zhiming; Wu, Qing; Tang, Jianfang; Wang, Lisha; Chen, Xiangyu; Chen, Cheng; Zhang, Yanyan; Yao, Wei; Ye, Jianqiang*; He, Ran*; Huang, Jun*; Ye, Lilin*Journal for ImmunoTherapy of Cancer, 2022, 10(5): e004022.被引 7
- Tumor-specific memory CD8+ T cells are strictly resident in draining lymph nodes during tumorigenesisLiu, Qiao; Ran, Ling; Yue, Zhengliang; Su, Xingxing; Wang, Lisha; Wen, Shuqiong; Lei, Shun; Yang, Xiaofan; Zhang, Yan; Hu, Jianjun; Tang, Jianfang; Li, Zhirong; Hu, Li; Zhu, Bo; Xu, Lifan*; Ye, Lilin*; Huang, Qizhao*Cellular & Molecular Immunology, 2023, 20(4): 423-426.被引 3
